Incorporating value-based care into oncology

EK Seymour, JA de Souza, AM Fendrick - The Cancer Journal, 2020 - journals.lww.com
Value-based care within insurance design utilizes evidence-based medicine as a means of
defining high-value versus low-value diagnostics and treatments. The goals of value-based …

Oncology medical home: ASCO and COA standards

K Woofter, EB Kennedy, K Adelson, R Bowman… - JCO Oncology …, 2021 - ascopubs.org
PURPOSE: To provide Standards on the basis of evidence and expert consensus for a pilot
of the Oncology Medical Home (OMH) certification program. The OMH model is a system of …

Patient-reported outcomes: understanding surgical efficacy and quality from the patient's perspective

JI Billig, ED Sears, BN Travis, JF Waljee - Annals of surgical oncology, 2020 - Springer
In surgery, quality assessment encourages improved care delivery, better outcomes, and
helps determine surgical efficacy. Quality is important from a patient, provider, payer, and …

Negotiated Rates for Surgical Cancer Care in the Era of Price Transparency—Prices Reflect Market Competition

DH Rochlin, NM Rizk, E Matros, TH Wagner… - Annals of …, 2024 - journals.lww.com
Objective: To measure commercial price variation for cancer surgery within and across
hospitals. Background: Surgical care for solid-organ tumors is costly, and negotiated …

ASCO Domestic Quality Programs

I Makhoul, S Power, C Smith, T Niece… - JCO Global …, 2024 - ascopubs.org
A growing sense of the need to define good-quality cancer care has emerged in the past
decade of the 20th century. The goals were to assess, improve, and reward quality …

The National Cancer Institute's role in advancing health-care delivery research

PB Jacobsen, J de Moor, VP Doria-Rose… - JNCI: Journal of the …, 2022 - academic.oup.com
Improvements in cancer care delivery have the potential to reduce morbidity and mortality
from cancer, however, challenges to delivery of recommended care limit progress. These …

The oncology care model—why it works and why it could work better: accounting for novel therapies in value-based payment

AJ Lyss, SN Supalla, SM Schleicher - JAMA oncology, 2020 - jamanetwork.com
Value-based payment models (VBPMs) have become increasingly prevalent in oncology.
The most robust example is the Oncology Care Model (OCM), a cancerspecific, 5-year …

Risk stratification and outreach to hematology/oncology patients during the COVID-19 pandemic

CK Osterman, T Triglianos, GS Winzelberg… - Supportive Care in …, 2021 - Springer
Purpose Cancer patients have many medical and psychosocial needs, which may increase
during the COVID-19 pandemic. We sought to (1) risk-stratify hematology/oncology patients …

Better Together? Costs of First-line Chemoimmunotherapy for Advanced Non-Small Cell Lung Cancer.

J Kish, D Liassou, J Hartman… - American Journal of …, 2023 - search.ebscohost.com
OBJECTIVES: Recent advances have created options for first-line (1L) treatment of
advanced/metastatic non--small cell lung cancer (aNSCLC). The study objectives were to …

Incorporating Cost Measures Into the Merit-Based Incentive Payment System: Implications for Oncologists

VR Patel, TB Cwalina, N Nortj , S Mullangi… - JCO Oncology …, 2023 - ascopubs.org
PURPOSE The Merit-Based Incentive Payment System (MIPS) is currently the only federally
mandated value-based payment model for oncologists. The weight of cost measures in …